Zhangzhou Pientzehuang Pharmaceutical Past Earnings Performance
Past criteria checks 4/6
Zhangzhou Pientzehuang Pharmaceutical has been growing earnings at an average annual rate of 18.1%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 14.2% per year. Zhangzhou Pientzehuang Pharmaceutical's return on equity is 20.5%, and it has net margins of 28.3%.
Key information
18.1%
Earnings growth rate
18.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 14.2% |
| Return on equity | 20.5% |
| Net Margin | 28.3% |
| Next Earnings Update | 17 Aug 2024 |
Revenue & Expenses Breakdown
How Zhangzhou Pientzehuang Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 10,600 | 3,002 | 1,166 | 228 |
| 31 Dec 23 | 10,058 | 2,797 | 1,162 | 232 |
| 30 Sep 23 | 9,678 | 2,825 | 857 | 267 |
| 30 Jun 23 | 9,317 | 2,699 | 779 | 236 |
| 31 Mar 23 | 8,975 | 2,553 | 797 | 245 |
| 31 Dec 22 | 8,694 | 2,472 | 808 | 230 |
| 30 Sep 22 | 8,526 | 2,473 | 878 | 245 |
| 30 Jun 22 | 8,595 | 2,631 | 941 | 249 |
| 31 Mar 22 | 8,368 | 2,556 | 1,024 | 256 |
| 31 Dec 21 | 8,022 | 2,432 | 1,034 | 200 |
| 30 Sep 21 | 7,553 | 2,354 | 955 | 103 |
| 30 Jun 21 | 7,113 | 1,922 | 1,061 | 104 |
| 31 Mar 21 | 6,798 | 1,769 | 1,001 | 89 |
| 31 Dec 20 | 6,511 | 1,672 | 984 | 98 |
| 30 Sep 20 | 6,451 | 1,594 | 1,017 | 126 |
| 30 Jun 20 | 6,074 | 1,493 | 901 | 122 |
| 31 Mar 20 | 5,952 | 1,438 | 865 | 132 |
| 31 Dec 19 | 5,722 | 1,374 | 799 | 119 |
| 30 Sep 19 | 5,522 | 1,332 | 712 | 141 |
| 30 Jun 19 | 5,257 | 1,272 | 659 | 125 |
| 31 Mar 19 | 5,028 | 1,221 | 645 | 108 |
| 31 Dec 18 | 4,766 | 1,143 | 629 | 101 |
| 30 Sep 18 | 4,555 | 1,052 | 685 | 74 |
| 30 Jun 18 | 4,365 | 991 | 659 | 98 |
| 31 Mar 18 | 4,076 | 907 | 647 | 82 |
| 31 Dec 17 | 3,714 | 807 | 611 | 70 |
| 30 Sep 17 | 3,428 | 730 | 564 | 41 |
| 30 Jun 17 | 3,101 | 664 | 571 | 0 |
| 31 Mar 17 | 2,700 | 616 | 520 | 0 |
| 31 Dec 16 | 2,309 | 536 | 489 | 0 |
| 30 Sep 16 | 2,180 | 575 | 426 | 0 |
| 30 Jun 16 | 2,032 | 520 | 395 | 0 |
| 31 Mar 16 | 1,975 | 497 | 363 | 0 |
| 31 Dec 15 | 1,886 | 467 | 339 | 0 |
| 30 Sep 15 | 1,698 | 513 | 300 | 0 |
| 30 Jun 15 | 1,503 | 474 | 280 | 0 |
| 31 Mar 15 | 1,455 | 440 | 269 | 0 |
| 31 Dec 14 | 1,454 | 439 | 262 | 0 |
| 30 Sep 14 | 1,409 | 373 | 275 | 0 |
| 30 Jun 14 | 1,446 | 422 | 263 | 0 |
| 31 Mar 14 | 1,436 | 438 | 252 | 0 |
| 31 Dec 13 | 1,396 | 430 | 241 | 0 |
| 30 Sep 13 | 1,348 | 423 | 204 | 0 |
Quality Earnings: 600436 has high quality earnings.
Growing Profit Margin: 600436's current net profit margins (28.3%) are lower than last year (28.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600436's earnings have grown by 18.1% per year over the past 5 years.
Accelerating Growth: 600436's earnings growth over the past year (17.6%) is below its 5-year average (18.1% per year).
Earnings vs Industry: 600436 earnings growth over the past year (17.6%) exceeded the Pharmaceuticals industry -0.8%.
Return on Equity
High ROE: 600436's Return on Equity (20.5%) is considered high.